Provectus Biopharmaceuticals Inc (PVCT)

[Pokerpro05]

Translation according to my computer...

Purovu~ekutasu countries drugs - exchanging a memorandum of understanding with Kuni-yaku Isshin Chemical Industires Co., Ltd. and China pharmaceutical industry research institute
Date: 08/21/2014 @ 5:46 AM
Source: Business Wire
Stock: Provectus Biopharmaceuticals, Inc. (PVCT)
Quote: .8997 -0.0003 (-0.03%) @ 10:26 AM
Purovu~ekutasu countries drugs - exchanging a memorandum of understanding with Kuni-yaku Isshin Chemical Industires Co., Ltd. and China pharmaceutical industry research institute
Print
Alert
Provectus Biopharmaceuticals, (AMEX: PVCT)
Intraday Stock Chart
Today: Thursday 21 August 2014

Click Here for more Provectus Biopharmaceuticals, Charts.
Start negotiations on PV-10 license in China

(BUSINESS WIRE) - Bio-pharmaceutical companies Purovu~ekutasu Biopharmaceuticals of development stage in Oncology dermatology field: Today, (NYSE MKT PVCT) (http://www.pvct.com) (Purovu~ekutasu) country drugs - China pharmaceutical industry Ken total Institute (Sinopharm-China State Institute of Pharmaceutical Industry, hereinafter referred to as "country -CSIPI drugs") Kuni-yaku Isshin drug Co., Ltd. and (Sinopharm A-THINK Pharmaceutical Co., Ltd., hereinafter referred to as "country , today announced that it has signed a memorandum of understanding with the medicine Isshin "). Are in a position to lead the Pharmaceutical Research all plants in China country medicine -CSIPI, country drugs Isshin Ken development, manufacturing and sales for a comprehensive platform of the injectable anti-tumor drug drugs group in the country (Sinopharm Group) within It is the presence of only as.

The important factor in this Memorandum of Understanding, we would like to obtain a exclusive license that country drug Isshin countries and drugs -CSIPI to commercialize PV-10 in China (PRC), there is a willingness of the license granted PVCT It is the thing that.

Assuming an additional negotiations, approval is required in-house due diligence, and regulations authorities, stakeholders, we aim to conclude a formal license agreement with three months ahead. In addition, officials will work (prepaid, milestones, royalties) for the use of technology by country Purovu~ekutasu drugs Isshin detail, in China the license, the process of commercialization, payment for Purovu~ekutasu. Purovu~ekutasu The plan to produce in the United States PV-10, country Isshin drugs will be sold in China PV-10.

This Memorandum of Understanding is intended in accordance with the laws of China, it is the result of negotiations that Network 1 Financial Securities, who is a financial advisor of Purovu~ekutasu has led. Officials was hold meetings in the country drugs -CSIPI headquarters of Shanghai, China. Senior staff of Purovu~ekutasu and senior executives of the country through drug population attended the meeting. Purovu~ekutasu was submitted to clinical and non-clinical data on drug PV-10 of our own. And scientists specializing in country drug Isshin countries and drugs -CSIPI was debated extensively considerable professional and ve Kuta steam. "Officials, is intended as innovative drugs PV-10 is an advanced and constitutes a global trend of Oncology Research, a wide range of economic and social benefits to the (China) market in this Memorandum of Understanding It has been described as "agreed recognition that would bring.

Furthermore, in addition to the results obtained in clinical trials of PV-10 to target melanoma, breast cancer, liver cancer, and systemic effects on the efficacy of the human immune, "All parties PV-10 in this Memorandum of Understanding It has been described and There "admitted the possibility that can be applied lung cancer, pancreatic cancer, prostate cancer, kidney cancer, in other indications.

Customary provisions of confidential information, advertising, intellectual property is included in this memorandum of understanding, and is not (except for the provisions not important specific) binding on the parties. Until replaced by the definitive agreement, until notice in writing one month before due or to any of the country drugs or Purovu~ekutasu, one of up to 90 days after the signing of this MOU, this MOU, force until the shortest period I will keep.

For countries drugs

Medical and health care group, China's largest Sinopharm total Ltd (country drugs), China State-owned Assets Supervision and Administration Commission of the State Council (SASAC) is through direct, sales, distribution, retail and science of health care products I've been with core competencies in the Ken manufacturing. In addition to the 10 subsidiaries of the holding company and a wholly-owned subsidiary, as the five listed companies, national drug Holdings Co., Ltd. (01099.HK), country drugs Pharmaceutical Group Co., Ltd. (600511.SH), country drugs Beijing Tiantan Biological I am suffering under the umbrella product Co., Ltd. (600161.SH), Shanghai Modern Pharmaceutical Co., Ltd. (600420.SH), country drugs group match drugs Industry Co., Ltd (200028.SZ). Total sales of the country drug was give a 160 billion RMB in 2012. It has become a pharmaceutical company in China only total sales get a 100 billion RMB.

Please see the http://www.sinopharm.com for more information.

For China the pharmaceutical industry KenSo salon - country drug

Shanghai Research Institute of the pharmaceutical industry of the founding in 1957 is the predecessor of China pharmaceutical industry Research institute - country drugs. Standing at the top of China as manifesting based on bio-science lab and pharmaceutical applications, drug -CSIPI country is the core drug development, sales, logistics and science Research innovative health care products I have a business. This is one country pharmaceutical technology innovation bases (National Pharmaceutical Technology Innovation Bases).

Please see the http://www.csipi.com.cn for more information.

For countries drugs Isshin drug Co., Ltd.

Isshin country drug drug Co., Ltd founded in 1997 has been devoted to the development of anti-tumor, anti-hepatitis product for injection. With anti-tumor anti-viral drug development and manufacturing integrated platform only, country drugs Isshin has with core competencies in research and development, manufacturing, sales in China of a new tumor therapeutic agent in the country drug population.

Network 1 Financial Securities, Inc. About

Network 1 Financial Securities of the founding in 1983, as the investment bank of full-service, Inc. is committed to support of privately held companies and publicly traded companies that invest in international capital markets have experienced rapid changes.

Members in the United States financial transactions GoTadashi mechanism (FINRA), NASDAQ stock market, Securities Investor Protection Corporation (SIPC), Network 1 Financial Securities will have been registered the United States Securities and Exchange Commission (SEC) as a broker-dealer You.

Please see the http://www.network1financial.com for more information.

For Purovu~ekutasu-Biopharmaceuticals

Purovu~ekutasu-Biopharmaceuticals, specializes in the development of therapeutic agents in the field of dermatology and oncology. By the Dane in (intralesional administration) for injection into solid tumors, new cancer investigational drug PV-10 of the Company, has been to reduce the potential for systemic side effects. We are concentrating forces melanoma, breast cancer, liver cancer in oncology. The Company has obtained from the FDA orphan drug designation to the indication of hepatocellular carcinoma and melanoma. Skin disease for topical administration investigational drug PH-10, our progress clinical trials to target atopic dermatitis and psoriasis. And the second phase test of PV-10 as a metastatic melanoma treatment drug, atopic dermatitis and Purovu~ekutasu has completed the second phase of the trial of PH-10 as a topical treatment for psoriasis. Information and test these, about clinical trials of our other can be found in the NIH registry (www.clinicaltrials.gov). For more information about Purovu~ekutasu, or visit the (www.pvct.com) our web site, please contact Porter, LeVay & Rose, until Inc..

In this document, "forward-looking statements" as that term is defined in the federal securities laws include: forward-looking statements. These statements are intended to reflect knowledge at the present time through the team, assumptions, opinions, estimates, expectations, future performance, results, and represents the current beliefs through team of trends, "expected to "think" ", which may be" "estimate", "and" expected "and" intended ", it is" possible "and" Project ", and" prediction ", and" plan "," going there are times when it can be identified by the use of similar expressions, and other expressions such as "is. And the influence of the number of risks and uncertainties, may differ significantly from those actual results have been shown in the forward-looking statements by the risks and uncertainties of these forward-looking statements. Readers should not place undue reliance on forward-looking statements. These descriptions are intended as of the date of this document, the Company does not assume any obligation to update these descriptions since that date.

The risks and uncertainties that could cause the case to be materially different from those that actual results are described in the forward-looking statements, December (2013 those that are described in the documents we have filed with the Securities and Exchange Commission addition to), including those described in the form 10-Q quarterly report for the year-end and in Item 1A of the Form 10-K annual report to ending on the 31st, and March 31, 2014, include the following: are included.

• And our judgment ruled against the FDA guidance for the phase III trial of PV-10 for the treatment of locally advanced cutaneous melanoma, whether proceed alone should proceed in partnership with partners, third phase, such as the The costs associated with the test if it was tested required.
• If the license is appropriate in consideration of the mechanism and timing of license, or license our candidate therapeutics PV-10 of other solid tumors and melanoma, such as liver cancer, melanoma and other solid, such as liver cancer our judgment of whether to commercialize in-house PV-10 for the treatment of tumors.
• Skin disease therapeutic drug candidates PH-10 Company, based on the results of a phase 2 trial of interest psoriasis and atopic dermatitis, while promoting further development in parallel Ken mechanism of action, the present our ability to license the agent.
• We expect that prior to commercialization, biotechnology companies or pharmaceutical companies as a purchase candidate companies purchase, but if it is decided to commercialize in-house PH-10 and PV-10 and / or additional our ability to raise capital such.
The official version of this press release is the original language version. It is one that has been provided for the purpose of the convenience of the reader, the translation language version, does not have legal effect. When you wish to use as the article translation language version, we ask that you do against the original language version is the only version that has legal effect.



Provectus Biopharmaceuticals, Inc.
Peter R. Culpepper, CFO, COO
866-594-5999 # 30
or
Porter, Levay & Rose, Inc.
Marlon Nurse, DM, SVP - Investor Relations
212-564-4700
or
Bill Gordon - Media Relations
212 -724-6312